Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin

Skin Aging Clinical Trial

Official title:

Topical Vitamin A (All-trans Retinol) Versus Vehicle Cream in the Treatment of Aged Skin

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00272610
• Other study ID #: Derm 443
• Status: Completed
• Phase: Phase 2
• First received: January 3, 2006
• Last updated: June 23, 2015
• Start date: September 2000
• Est. completion date: February 2002

Study information

• Verified date: September 2006
• Source: University of Michigan
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The objectives of this study are to evaluate the safety and efficacy of 0.5% retinol (Vitamin A) versus it's vehicle cream in the treatment and prevention of skin aging and Bateman's Purpura (bruising).

Description:

Human skin becomes thinner and looses its elasticity with increasing age. These features of intrinsic skin aging are due to reduction in collagen synthesis with a concomitant increase in collagen and elastic fiber breakdown by matrix metalloproteinase (MMPs). In addition to these changes that occur simply from the passage of time, skin that is chronically exposed to the sun undergoes accelerated aging process referred to as photoaging. Here sun causes further alterations in dermal matrix by transiently inducing MMPs with each irradiation. Bateman's purpura (BP) is a bruised lesion that is commonly seen on the sun-exposed extensor surfaces of forearms and hands in elderly individuals. It is of no medical significance. However, to those afflicted, BP is often a great source of distress for its unsightliness and the obvious sign of aging it represents. The pathophysiology of BP has not been rigorously studied. Its exclusive presence on the sun-exposed surfaces of frequently traumatized areas suggests that photoaging associated loss of supporting structures around cutaneous blood vessels render the vessels easily torn by shearing injuries, thus causing purpura.

Topical use of tretinoin (RA) 0.1% cream has been demonstrated to improve clinical as well as histologic changes associated with photodamaged skin. Improvement in skin wrinkles by RA appears to be related to dermal changes. RA causes accumulation of epidermal and dermal TGF-alpha 1, a cytokine known to stimulate the synthesis of collagen I and VII, both of which, by ultrastructural criteria, are increased by RA in photodamaged skin. In fact, induction of dermal collagen formation by topically applied RA has been demonstrated in animal studies, and this has been confirmed in human studies. Therefore, it is postulated that topical treatment of BP prone skin with RA would buttress up cutaneous blood vessels by increasing the supporting collagenous structures around them. Such vessels ought to withstand shearing forces better, which would lead to some protection against the development of BP.

Retinol is a precursor to RA. When applied to human skin, it mediates all the effects that RA causes, but does so with much less skin irritation. Therefore, it is expected to be better tolerated by elderly skin than RA. In a seven day treatment study of elderly patients, retinol has been shown to induce mRNA levels of procollagen molecules in human skin in vivo. Therefore, it is hypothesized to improve the thin skin of elderly by increasing the synthesis of more collagen in both the photoaged, and hence improve BP, and the intrinsically aged human skin without causing significant irritant skin reaction.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 50
• Est. completion date: February 2002
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 70 Years and older

Eligibility

Inclusion Criteria:

• Male and female

• 70 years of age or older

• history of Bateman's purpura on arms

• Relatively good general health and able to perform daily tasks

Exclusion Criteria:

• Sensitivity to any formulation ingredients

• History of Cardiovascular disease with continuing deficits (example: partial paralysis)

• Participated in any clinical trials within last 30 days

• Topical steroids or other drugs two weeks prior to study entry (short-term application of topical antimicrobials is allowed)

• Hormone replacement therapy within last 6 months.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Purpura
• Skin Aging

Intervention

Drug:
• 0.4% Retinol Cream

Locations

Country	Name	City	State
United States	University of Michigan	Ann Arbor	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
University of Michigan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Surface Roughness
Primary	Fine wrinkles
Primary	Hyperpigmentation
Primary	Purpura
Secondary	Collagen content of skin biopsies
Secondary	Glycosaminoglycan expression
Secondary	CRABP-II expression